| Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export P Lei, S Ayton, DI Finkelstein, L Spoerri, GD Ciccotosto, DK Wright, ... Nature medicine 18 (2), 291-295, 2012 | 661 | 2012 |
| Tau-mediated iron export prevents ferroptotic damage after ischemic stroke QZ Tuo, P Lei, KA Jackman, XL Li, H Xiong, ZY Liuyang, L Roisman, ... Molecular psychiatry 22 (11), 1520-1530, 2017 | 618 | 2017 |
| Overcoming the blood–brain barrier: the role of nanomaterials in treating neurological diseases D Furtado, M Björnmalm, S Ayton, AI Bush, K Kempe, F Caruso Advanced materials 30 (46), 1801362, 2018 | 600 | 2018 |
| Current state of Alzheimer’s fluid biomarkers JL Molinuevo, S Ayton, R Batrla, MM Bednar, T Bittner, J Cummings, ... Acta neuropathologica 136, 821-853, 2018 | 562 | 2018 |
| A delicate balance: Iron metabolism and diseases of the brain D Hare, S Ayton, A Bush, P Lei Frontiers in aging neuroscience 5, 34, 2013 | 460 | 2013 |
| Metallostasis in Alzheimer's disease S Ayton, P Lei, AI Bush Free Radical Biology and Medicine 62, 76-89, 2013 | 401 | 2013 |
| Ferroptosis and its potential role in the physiopathology of Parkinson’s Disease L Mahoney-Sánchez, H Bouchaoui, S Ayton, D Devos, JA Duce, ... Progress in neurobiology 196, 101890, 2021 | 371 | 2021 |
| Ferroptosis and cell death mechanisms in Parkinson's disease SJ Guiney, PA Adlard, AI Bush, DI Finkelstein, S Ayton Neurochemistry international 104, 34-48, 2017 | 343 | 2017 |
| Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology S Ayton, Y Wang, I Diouf, JA Schneider, J Brockman, MC Morris, AI Bush Molecular psychiatry 25 (11), 2932-2941, 2020 | 328 | 2020 |
| Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE S Ayton, NG Faux, AI Bush Nature communications 6 (1), 6760, 2015 | 328 | 2015 |
| The essential elements of Alzheimer’s disease P Lei, S Ayton, AI Bush Journal of Biological Chemistry 296, 2021 | 290 | 2021 |
| Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease S Ayton, P Lei, JA Duce, BXW Wong, A Sedjahtera, PA Adlard, AI Bush, ... Annals of neurology 73 (4), 554-559, 2013 | 284 | 2013 |
| Iron and Alzheimer’s disease: an update on emerging mechanisms DJR Lane, S Ayton, AI Bush Journal of Alzheimer's Disease 64 (s1), S379-S395, 2018 | 273 | 2018 |
| Cerebral quantitative susceptibility mapping predicts amyloid-β-related cognitive decline S Ayton, A Fazlollahi, P Bourgeat, P Raniga, A Ng, YY Lim, I Diouf, ... Brain 140 (8), 2112-2119, 2017 | 266 | 2017 |
| Tau protein: relevance to Parkinson's disease P Lei, S Ayton, DI Finkelstein, PA Adlard, CL Masters, AI Bush The international journal of biochemistry & cell biology 42 (11), 1775-1778, 2010 | 263 | 2010 |
| GSK‐3 in neurodegenerative diseases P Lei, S Ayton, AI Bush, PA Adlard International journal of Alzheimer’s disease 2011 (1), 189246, 2011 | 196 | 2011 |
| Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion Q Tuo, Y Liu, Z Xiang, HF Yan, T Zou, Y Shu, X Ding, J Zou, S Xu, F Tang, ... Signal transduction and targeted therapy 7 (1), 59, 2022 | 194 | 2022 |
| The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease LW Hung, VL Villemagne, L Cheng, NA Sherratt, S Ayton, AR White, ... Journal of Experimental Medicine 209 (4), 837-854, 2012 | 192 | 2012 |
| Nigral iron elevation is an invariable feature of Parkinson’s disease and is a sufficient cause of neurodegeneration S Ayton, P Lei BioMed research international 2014 (1), 581256, 2014 | 173 | 2014 |
| Motor and cognitive deficits in aged tau knockout mice in two background strains P Lei, S Ayton, S Moon, Q Zhang, I Volitakis, DI Finkelstein, AI Bush Molecular neurodegeneration 9, 1-12, 2014 | 162 | 2014 |